Future of drugs-Diabetes_Bexagliflozin
This series will take you through the future of drugs. Which drugs are in the pipeline of which company, which clinical phase are they in during trials? We have all the answers.
We
are going to start with diabetes since it is one of the biggest monsters plaguing
India since decades. According to
statistics and surveys, India has the most number of diabetics in the world.
Hence,
in this series, we are going to take you through the most promising few
candidates against diabetes in the future. These drugs might shape the Pharma market
for diabetes and we can be rest assured that we might have newer drugs for this
deadly disease.
Drug Name
|
Bexagliflozin
|
Structure
|
|
Drug
Code
|
EGT
0001442
|
Synonym
|
THR-1442
|
Molecular
Formula
|
C24H29ClO7
|
Innovator
|
Theracos
(US based company)
|
Condition
|
Type
2 Diabetes Mellitus
|
Mechanism
of Action
|
Sodium-glucose
transporter 2 inhibitor
|
Clinical
Phase
|
III in USA
|
Comments
Post a Comment